circle

A PIPELINE POWERED BYPASSION

PUBLICATIONS AND PRESENTATIONS

Rationale and Design for a Phase II Study Evaluating the Effect of the Cardiac Myosin Activator, CK-1827452, on Cardiac Function, Hemodynamics, and Myocardial Oxygen Consumption in Patients with Heart Failure

Poster, 2008 Heart Failure Society of America Annual Meeting (HFSA)
Toronto, Ontario, Canada
Parker JD, Michaels AD, Kass DA, Wolff AA, Felker GM and Malik FI
September 2008

First Clinical Trial of the Selective Cardiac Myosin Activator, CK-1827452, in Heart Failure: Effect of Dose and Plasma Concentration on Systolic Function

Poster, European Society of Cardiology (ESC) Congress 2008
Cleland JGF, Nifontov EM, Mc Murray JJV, Senior R, Lang CC, Clarke CP, Francis D, Greenberg B, Mayet J, Monaghan M, Neyses L, Tsyrlin VA, Goldman JH, Teerlink JR, Brand G, Lee JH, Saikali KG, Wolff AA, Malik FI
August, 2008

The Cardiac Myosin Activator CK-1827452-Induced Myocyte Contractility is Unchanged in the Presence of β-Blockade

Poster, 2007 American Society of Cell Biology (ASCB) Conference
Washington, DC
Anderson RL, Pokrovskii M, Suekawa K, Rodriguez HM, Elias, KA
December 2007

Systolic Ejection Time Is a Sensitive Indicator of Left Ventricular Systolic Function During Treatment with the Selective Cardiac Myosin Activator, CK-1827452

Poster, 2007 Heart Failure Society of America Annual Meeting (HFSA)
Washington, DC
Malik FI, Saikali KG, Clarke CP, Teerlink JR, Wolff AA
September 2007

Oral Bioavailability of the Selective Cardiac Myosin Activator CK-1827452: Chronic Oral Inotropic Therapy for Heart Failure

Poster, 2007 Annual Heart Failure Society of America Meeting (HFSA)
Washington, DC
Jerling M, Chew T, Escandon R, Lee J, Saikali K, Venables E, Clarke C, Malik F, Wolff A
September 2007